<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00732316</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000600347</org_study_id>
    <secondary_id>AMC-UUCM-2008-0037</secondary_id>
    <nct_id>NCT00732316</nct_id>
  </id_info>
  <brief_title>Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome</brief_title>
  <official_title>HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES AND MYELODYSPLASTIC SYNDROME - A PHASE 2 STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy and antithymocyte globulin before a donor stem&#xD;
      cell transplant helps stop the growth of cancer and abnormal cells. It may also stop the&#xD;
      patient's immune system from rejecting the donor's stem cells. The donated stem cells may&#xD;
      replace the patient's immune cells and help destroy any remaining cancer and abnormal cells&#xD;
      (graft-versus-tumor effect).&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well a donor stem cell transplant works after&#xD;
      busulfan, fludarabine, and antithymocyte globulin in treating patients with hematologic&#xD;
      cancer or myelodysplastic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To evaluate the efficacy of HLA-haploidentical familial donor hematopoietic cell&#xD;
           transplantation with a reduced-intensity conditioning regimen of busulfan, fludarabine&#xD;
           phosphate, and anti-thymocyte globulin in patients with hematologic malignancies or&#xD;
           myelodysplastic syndromes.&#xD;
&#xD;
      OUTLINE: Before receiving the reduced-intensity conditioning regimen, patients receive one&#xD;
      dose of intrathecal (IT) methotrexate, then leucovorin calcium IV or orally 4 hours after&#xD;
      methotrexate and every 6 hours for a total of 8 doses.&#xD;
&#xD;
        -  Reduced-intensity conditioning regimen: Patients receive busulfan IV over 6 hours on&#xD;
           days -7 and -6, fludarabine phosphate IV over 30 minutes on days -7 to -2,&#xD;
           anti-thymocyte globulin (ATG) IV over 4 hours on days -4 to -1, and methylprednisolone&#xD;
           IV over 30 minutes on days -4 to -1.&#xD;
&#xD;
        -  HLA-haploidentical familial donor hematopoietic stem cell transplantation (HSCT):&#xD;
           Patients undergo allogeneic HSCT over 1 hour on days 0 and 1.&#xD;
&#xD;
        -  Graft-versus-host disease (GVHD) prophylaxis: Patients receive cyclosporine IV* over 2-4&#xD;
           hours every 12 hours on days -1 to 30 followed by a taper until day 60 and methotrexate&#xD;
           IV on days 2, 4 , 7, and 12.&#xD;
&#xD;
      NOTE: *Cyclosporine can be given orally once oral medication can be tolerated&#xD;
&#xD;
        -  CNS prophylaxis: When blood counts recover, patients with acute leukemia or chronic&#xD;
           myelogenous leukemia in blastic crisis resume IT methotrexate once every 2 weeks for a&#xD;
           total of 4 doses (including the dose given before the conditioning regimen) and&#xD;
           leucovorin calcium IV or orally 4 hours after (each dose of methotrexate) and every 6&#xD;
           hours for a total of 8 doses.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for up to 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor response</measure>
    <time_frame>about 4-8 weeks after transplantation</time_frame>
    <description>leukemia CR, CR duration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Donor cell engraftment (neutrophil, platelet, and red blood cells)</measure>
    <time_frame>10-35 days after transplantation</time_frame>
    <description>neutrophi count over 500/ul</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and chronic graft-versus-host disease</measure>
    <time_frame>15-100 days; 100 days to 4 years</time_frame>
    <description>ocurrence of acute or chronic GVHD</description>
  </secondary_outcome>
  <enrollment type="Actual">54</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nonmyeloablative allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>administration of conditioning therapy including immunosuppressive agents plus alkylating agents and infusing hematopoietic progenitor cells collected from the donor</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>infusion of donor hematopoietic cells collected by leukapheresis after mobilization with growth factor</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following hematological malignancies:&#xD;
&#xD;
               -  Acute leukemia, including any of the following:&#xD;
&#xD;
                    -  Refractory acute leukemia&#xD;
&#xD;
                    -  Acute leukemia beyond first remission&#xD;
&#xD;
                    -  Acute leukemia in first remission with intermediate to poor prognostic&#xD;
                       features as suggested by chromosomal findings&#xD;
&#xD;
               -  Chronic myelogenous leukemia (CML)&#xD;
&#xD;
                    -  Second chronic phase&#xD;
&#xD;
                    -  Accelerated phase&#xD;
&#xD;
                    -  Blastic phase&#xD;
&#xD;
               -  Myelodysplastic syndrome (MDS)&#xD;
&#xD;
                    -  High-risk MDS (refractory anemia with excess blasts [RAEB], RAEB in&#xD;
                       transformation, and chronic myelomonocytic leukemia) can be transplanted&#xD;
                       without prior therapy or after prior therapy failure with hypomethylating&#xD;
                       agents&#xD;
&#xD;
                    -  Low-risk MDS can be considered for transplantation after prior therapy&#xD;
                       failure with immunosuppressive or hypomethylating agents&#xD;
&#xD;
          -  No willing, suitable HLA-matched donor in family or in donor registries&#xD;
&#xD;
               -  Patients with active hematologic malignancy, who are felt to be in urgent need of&#xD;
                  allogeneic hematopoietic cell transplantation, can enroll without a search for&#xD;
                  HLA-matched unrelated donors&#xD;
&#xD;
          -  Related donor with HLA-haploidentical mismatch at 3 or less of 6 loci available&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 70-100%&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
          -  AST &lt; 3 times upper limit of normal&#xD;
&#xD;
          -  Ejection fraction &gt; 40% by MUGA&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoo H. Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center - University of Ulsan College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Lee KH, Lee JH, Lee JH, Kim DY, Seol M, Lee YS, Kang YA, Jeon M, Hwang HJ, Jung AR, Kim SH, Yun SC, Shin HJ. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood. 2011 Sep 1;118(9):2609-17. doi: 10.1182/blood-2011-02-339838. Epub 2011 Jun 28.</citation>
    <PMID>21715313</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>August 8, 2008</study_first_submitted>
  <study_first_submitted_qc>August 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2008</study_first_posted>
  <last_update_submitted>July 16, 2012</last_update_submitted>
  <last_update_submitted_qc>July 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Kyoo-Hyung Lee</investigator_full_name>
    <investigator_title>Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

